Results 241 to 250 of about 22,642,428 (383)

Phosphodiesterase 3 inhibitors boost bone outgrowth

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose C‐type natriuretic peptide (CNP) stimulates skeletal growth by acting on the growth plates of long bones, and a CNP variant is clinically used for achondroplasia treatment. We previously reported that CNP stimulates the autonomic Ca2+ influx mediated by TRPM7 channels in growth plate chondrocytes to facilitate extracellular ...
Takaaki Kawabe   +11 more
wiley   +1 more source

GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger

open access: yesBritish Journal of Pharmacology, EarlyView.
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng   +3 more
wiley   +1 more source

Pancreatic Panniculitis Without Pancreatopathy: A Rare Complication of Splenic Vein Stenting for Portal Hypertension in Myeloproliferative Syndrome

open access: yes
United European Gastroenterology Journal, EarlyView.
Eliza Butnaru   +3 more
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy